Pharma Mar hereby informs users that it uses cookies when the user browses through the various screens and pages of the website. These small data files are generated on the user’s computer and allow us to obtain useful information to personalize the website.

Cookies are only associated with the browser of a specific computer (anonymous user), do not collect any information from the computer and do not in themselves reveal the user’s location or name. Cookies allow Pharma Mar to recognize the browsers of registered users once they have registered for the first time, allowing them to avoid registering every time they access the areas and services reserved exclusively for them. If you do not want a cookie to be installed on your hard disk, please set up your computer browser not to accept them. Please note, however, that the quality of website operations may be diminished.

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.

Shareholders and Investors

Financial Information of the Company, stock information, official notices to the CNMV (Spanish Securities & Exchange Commission), product portfolio and other information.


If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom